A Global Building Occupant Behavior Database.

This paper introduces a database of 34 field-measured building occupant behavior datasets collected from 15 countries and 39 institutions across 10 climatic zones covering various building types in both commercial and residential sectors. This is a comprehensive global database about building occupant behavior. The database includes occupancy patterns (i.e., presence and people count) and occupant behaviors (i.e., interactions with devices, equipment, and technical systems in buildings). Brick schema models were developed to represent sensor and room metadata information. The database is publicly available, and a website was created for the public to access, query, and download specific datasets or the whole database interactively. The database can help to advance the knowledge and understanding of realistic occupancy patterns and human-building interactions with building systems (e.g., light switching, set-point changes on thermostats, fans on/off, etc.) and envelopes (e.g., window opening/closing). With these more realistic inputs of occupants' schedules and their interactions with buildings and systems, building designers, energy modelers, and consultants can improve the accuracy of building energy simulation and building load forecasting.

Toward human-centric urban infrastructure: Text mining for social media data to identify the public perception of COVID-19 policy in transportation hubs.

The COVID-19 pandemic has made transportation hubs vulnerable to public health risks. In response, policies using nonpharmaceutical interventions have been implemented, changing the way individuals interact within these facilities. However, the impact of building design and operation on policy efficacy is not fully discovered, making it critical to investigate how these policies are perceived and complied in different building spaces. Therefore, we investigate the spatial drivers of user perceptions and policy compliance in airports. Using text mining, we analyze 103,428 Google Maps reviews of 64 major hub airports in the US to identify representative topics of passenger concerns in airports (i.e., Staff, Shop, Space, and Service). Our results show that passengers express having positive experiences with Staff and Shop, but neutral or negative experiences with Service and Space, which indicates how building design has impacted policy compliance and the vulnerability of health crises. Furthermore, we discuss the actual review comments with respect to 1) spatial design and planning, 2) gate assignment and operation, 3) airport service policy, and 4) building maintenance, which will construct the foundational knowledge to improve the resilience of transportation hubs to future health crises.

The Building Data Genome Project 2, energy meter data from the ASHRAE Great Energy Predictor III competition.

This paper describes an open data set of 3,053 energy meters from 1,636 non-residential buildings with a range of two full years (2016 and 2017) at an hourly frequency (17,544 measurements per meter resulting in approximately 53.6 million measurements). These meters were collected from 19 sites across North America and Europe, with one or more meters per building measuring whole building electrical, heating and cooling water, steam, and solar energy as well as water and irrigation meters. Part of these data was used in the Great Energy Predictor III (GEPIII) competition hosted by the American Society of Heating, Refrigeration, and Air-Conditioning Engineers (ASHRAE) in October-December 2019. GEPIII was a machine learning competition for long-term prediction with an application to measurement and verification. This paper describes the process of data collection, cleaning, and convergence of time-series meter data, the meta-data about the buildings, and complementary weather data. This data set can be used for further prediction benchmarking and prototyping as well as anomaly detection, energy analysis, and building type classification.

Chronoamperometric Observation and Analysis of Electrocatalytic Ability of Single Pd Nanoparticle for Hydrogen Peroxide Reduction Reaction.

The current generated by the collision of a single nanoparticle (NP) of palladium (Pd) on a gold (Au) ultramicroelectrode (UME) surface was observed using an electrocatalytic amplification method. The hydrogen peroxide reduction reaction was used for the electrocatalytic reaction because the hydrogen peroxide reduction reaction has no gas-phase product, which would induce rapid signal decay. The electrocatalytic current resulting from a single Pd nanoparticle on the Au UME shows a staircase response with accompanying slow current decay. The applying potential and concentration of hydrogen peroxide were optimized for clear distinction of signal. The height of the current step and signal frequency were analyzed and compared with the theoretical expectation. The analysis of the electrocatalytic activity of single Pd NPs provides insight toward their future application.

Data on the interaction between thermal comfort and building control research.

This dataset contains bibliography information regarding thermal comfort and building control research. In addition, the instruction of a data-driven literature survey method guides readers to reproduce their own literature survey on related bibliography datasets. Based on specific search terms, all relevant bibliographic datasets are downloaded. We explain the keyword co-occurrences of historical developments and recent trends, and the citation network which represents the interaction between thermal comfort and building control research. Results and discussions are described in the research article entitled "Comprehensive analysis of the relationship between thermal comfort and building control research - A data-driven literature review" (Park and Nagy, 2018).

A multicenter, open-label, phase III study of Abcertin in Gaucher disease.

BACKGROUND: Gaucher disease (GD) is caused by a deficiency in the lysosomal enzyme glucocerebrosidase. Enzyme replacement therapy (ERT) is recommended for clinical improvement. METHODS: The efficacy and safety of a new imiglucerase, Abcertin, were assessed in 7 Egyptian patients with treatment-naïve type 1 GD. Each patient was administered a biweekly 60 U/kg dose of Abcertin for 6 months. The primary endpoint was the change in hemoglobin concentration. The secondary endpoints were changes from baseline in platelet counts, spleen and liver volumes, biomarker levels, skeletal parameters, and bone mineral density. RESULTS: The hemoglobin concentration increased by a mean of 1.96 ±â€Š0.91 g/dL (range 1.11-2.80 g/dL) or 20.6% (P = .001). Statistically significant increases in the platelet count and decreases in the spleen volume and biomarker levels were also observed. There were no severe drug-related adverse events. One patient developed anti-imiglucerase antibodies without neutralizing activity. CONCLUSION: Our study results demonstrate the efficacy and safety of Abcertin in patients with type 1 GD. This suggests that Abcertin can be an alternative ERT option for type 1 GD.

A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.

Gaucher disease is a lysosomal storage disease for which enzyme replacement therapy has proven to be effective. A switch-over clinical trial was performed to evaluate the efficacy and safety of Abcertin® (ISU Abxis, Seoul, Korea) in subjects with type 1 Gaucher disease who were previously treated with imiglucerase. Five Korean patients with type 1 Gaucher disease were enrolled. Previous doses of imiglucerase ranged from 30 to 55 U/kg every other week. The same dose of Abcertin® was administered to all patients for 24 weeks. Primary efficacy endpoints were changes in hemoglobin levels and platelet counts, and the secondary efficacy endpoints included changes in liver and spleen volumes, serum biomarkers, skeletal status and bone mineral density (BMD). During the study period, no statistically significant changes were observed in all parameters including hemoglobin levels and platelet counts, liver and spleen volumes, skeletal status and BMD. Abcertin® administration was continued in three patients for another 24 weeks as an extension of the study. Hemoglobin levels and platelet counts were maintained in all three patients. In conclusion, the efficacy and safety of Abcertin® are similar to those of imiglucerase, and Abcertin® is an effective therapeutic agent for patients with type 1 Gaucher disease (Clinical Trial Registry No. NCT02053896 at www.clinicaltrials.gov).

Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.

Parkinson's disease (PD) is an age-associated and progressive movement disorder that is characterized by dopaminergic neuronal loss in the substantia nigra and, at autopsy, by fibrillar alpha-synuclein inclusions, or Lewy bodies. Despite the qualitative correlation between alpha-synuclein fibrils and disease, in vitro biophysical studies strongly suggest that prefibrillar alpha-synuclein oligomers, or protofibrils, are pathogenic. Consistent with this proposal, transgenic mice that express human alpha-synuclein develop a Parkinsonian movement disorder concurrent with nonfibrillar alpha-synuclein inclusions and the loss of dopaminergic terminii. Double-transgenic progeny of these mice that also express human beta-synuclein, a homologue of alpha-synuclein, show significant amelioration of all three phenotypes. We demonstrate here that beta- and gamma-synuclein (a third homologue that is expressed primarily in peripheral neurons) are natively unfolded in monomeric form, but structured in protofibrillar form. Beta-synuclein protofibrils do not bind to or permeabilize synthetic vesicles, unlike protofibrils comprising alpha-synuclein or gamma-synuclein. Significantly, beta-synuclein inhibits the generation of A53T alpha-synuclein protofibrils and fibrils. This finding provides a rationale for the phenotype of the double-transgenic mice and suggests a therapeutic strategy for PD.